DK1656458T3 - Human autisme-susceptibilitetsgen og anvendelser deraf - Google Patents

Human autisme-susceptibilitetsgen og anvendelser deraf

Info

Publication number
DK1656458T3
DK1656458T3 DK04786410T DK04786410T DK1656458T3 DK 1656458 T3 DK1656458 T3 DK 1656458T3 DK 04786410 T DK04786410 T DK 04786410T DK 04786410 T DK04786410 T DK 04786410T DK 1656458 T3 DK1656458 T3 DK 1656458T3
Authority
DK
Denmark
Prior art keywords
autism
gene
diagnosis
prevention
treatment
Prior art date
Application number
DK04786410T
Other languages
English (en)
Inventor
Joerg Hager
Anne Philippi
Elke Roschmann
Original Assignee
Integragen Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Integragen Sa filed Critical Integragen Sa
Application granted granted Critical
Publication of DK1656458T3 publication Critical patent/DK1656458T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
DK04786410T 2003-08-22 2004-08-20 Human autisme-susceptibilitetsgen og anvendelser deraf DK1656458T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49691703P 2003-08-22 2003-08-22
US49690003P 2003-08-22 2003-08-22
PCT/IB2004/002995 WO2005019474A2 (en) 2003-08-22 2004-08-20 Human autism susceptibility gene and uses thereof

Publications (1)

Publication Number Publication Date
DK1656458T3 true DK1656458T3 (da) 2009-08-24

Family

ID=34221427

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04786410T DK1656458T3 (da) 2003-08-22 2004-08-20 Human autisme-susceptibilitetsgen og anvendelser deraf

Country Status (10)

Country Link
US (1) US20070134664A1 (da)
EP (1) EP1656458B1 (da)
JP (1) JP2007503210A (da)
AT (1) ATE431855T1 (da)
AU (1) AU2004267247B2 (da)
CA (1) CA2535754A1 (da)
DE (1) DE602004021186D1 (da)
DK (1) DK1656458T3 (da)
PT (1) PT1656458E (da)
WO (1) WO2005019474A2 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0504096D0 (en) * 2005-02-28 2005-04-06 Tipogen As Method
US20060258691A1 (en) * 2005-05-13 2006-11-16 Joseph Barbosa Methods and compositions for improving cognition
AU2007325403A1 (en) * 2006-11-07 2008-06-05 Lexicon Pharmaceuticals, Inc. Methods of treating cognitive impairment and dementia
EP2358907B1 (en) * 2008-11-12 2015-05-20 University of Utah Research Foundation Autism associated genetic markers
US8355927B2 (en) 2010-11-05 2013-01-15 Genomind, Llc Neuropsychiatric test reports
WO2010138796A2 (en) * 2009-05-29 2010-12-02 Genomind, Llc Methods for assessment and treatment of depression via utilization of single nucleotide polymorphisms analysis
US20110237537A1 (en) * 2009-05-29 2011-09-29 Lombard Jay L Methods for assessment and treatment of mood disorders via single nucleotide polymorphisms analysis
US8895511B2 (en) 2009-11-24 2014-11-25 St. Jude Children's Research Hospital Use of sarcoplasmic CA2+-ATPase type 2 protein for diagnosing and treating learning or mental disorders
WO2012078602A2 (en) * 2010-12-06 2012-06-14 Children's Medical Center Corporation Method for diagnosis and method of treatment of autism spectrum disorders and intellectual disability
EP2714932A4 (en) 2011-05-24 2015-06-10 Univ California DEGREGATED GENES IN AUTISM AS BIOMARKERS AND TARGETS FOR THERAPEUTIC PATHWAYS
CN114019161B (zh) * 2021-11-08 2022-08-09 陕西脉元生物科技有限公司 抗camk2a自身抗体的试剂在制备诊断神经系统症状相关疾病的试剂盒中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
WO1994019478A1 (en) 1993-02-22 1994-09-01 The Rockefeller University Production of high titer helper-free retroviruses by transient transfection
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
WO1998058082A1 (en) * 1997-06-17 1998-12-23 University Of Rochester Genetic polymorphisms which are associated with autism spectrum disorders
AU3773099A (en) * 1998-04-29 1999-11-16 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Identification of polymorphisms in the pctg4 region of xq13
WO2000068433A2 (en) * 1999-05-06 2000-11-16 Children's Hospital Of Los Angeles Autism gene
JP2005509416A (ja) * 2001-11-06 2005-04-14 ミレニアム・ファーマシューティカルズ・インコーポレイテッド ５７７、２０７３９、または５７１４５を使用して疼痛および有痛性傷害を処置するための方法および組成物
CA2364106A1 (fr) * 2001-11-30 2003-05-30 Christopher Gillberg Polynucleotide et proteine impliques dans la synaptogenese, variants de ceux-ci, et leurs applications therapeutiques et diagnostiques

Also Published As

Publication number Publication date
PT1656458E (pt) 2009-06-24
DE602004021186D1 (de) 2009-07-02
EP1656458A2 (en) 2006-05-17
WO2005019474A2 (en) 2005-03-03
AU2004267247B2 (en) 2010-02-18
AU2004267247A1 (en) 2005-03-03
JP2007503210A (ja) 2007-02-22
US20070134664A1 (en) 2007-06-14
EP1656458B1 (en) 2009-05-20
WO2005019474A3 (en) 2005-10-13
ATE431855T1 (de) 2009-06-15
CA2535754A1 (en) 2005-03-03

Similar Documents

Publication Publication Date Title
IL179751A0 (en) Human autism predisposition gene encoding a transcription factor and uses thereof
EP3498729A3 (en) Therapeutic targets for alzheimer's disease
WO2006087634A3 (en) Uses of human autism susceptibility gene encoding a kinase
ATE383853T1 (de) Arylessigsäuren und verwandte verbindungen zur behandlung von alzheimer-krankheit
DK1656458T3 (da) Human autisme-susceptibilitetsgen og anvendelser deraf
IL179831A0 (en) Human autism susceptibility gene encoding prkcb1 and uses thereof
WO2007132292A3 (en) Therapy for alzheimer's disease
BRPI0509477A (pt) compostos de sulfonamida para o tratamento de distúrbios neurodegenerativos
DK1863937T3 (da) Humant autisme-susceptibilitetsgen kodende for et transmembranprotein og anvendelser deraf
WO2006090288A3 (en) Human autism susceptibility genes encoding a neurotransmitter transporter and uses thereof
WO2001020026A3 (en) POLYMORPHISMS IN THE HUMAN hPXR GENE AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS
IL172229A (en) Use of pyrzolopyridines for the preparation of medicinal products to improve cognitive perception
WO2006003526A8 (en) Human autism susceptibility gene encoding otoa and uses thereof
WO2007071437A3 (en) Compositions and methods for treating inflammatory disorders
DE60324414D1 (de) Humanes fettleibigkeit suszeptibilitätsgen und deren verwendungen
ATE443160T1 (de) Für einen spannungsgesteuerten kaliumkanal kodierendes humanes adipositas- suszeptibilitätssgen und dessen verwendung
Schuch et al. The Genetic Basis of Autism Spectrum Disorder
DE602004030107D1 (de) Suszeptibilitätsgen für die alzheimersche krankheit
Youssof et al. Potential role of serotonin transporter gene (5-Htt) polymorphism in temporal lobe epilepsy susceptibility in egyptian patients.
DE60140934D1 (de) Polymorphismen des humanen cyp2b6 gens und deren verwendung in diagnostischen und therapeutischen anwendungen
Fraga et al. Aging, demented patients and polymorphisms in cytokine genes
WO2007044932A3 (en) Methods for indentification of inhibitors of enzyme activity
WO2005021787A3 (en) Human obesity susceptibility gene and uses thereof
BRPI0409688A (pt) análise e emprego de polimorfismos par1 para avaliação do risco de doenças cardiovasculares